ROBOSENSE
20.8.2021 13:02:04 CEST | Business Wire | Press release
RoboSense LiDAR, the leading Smart LiDAR Sensor provider announced the second-generation intelligent solid-state LiDAR RS-LiDAR-M1 (referred to as "M1") completed mass production and delivery to the designated project for the first time. Since the start of production (SOP) to vehicle manufacturer in June 2021, more than ten batches of deliveries have been completed. This is the first mass production of solid-state LiDAR in the world, and also marks the advent of “an era of mass production for LiDAR”.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210820005135/en/
Since July 2020, M1 has successively obtained designated cooperation orders for a number of mass-produced models around the world, including GAC Aion designated projects which official announced on last month . This mass production delivery for the designated automotive enterprises.
As the world's leading Smart LiDAR Sensor provider, RoboSense has completed iterations of five major and dozens of smaller versions on the smart solid-state LiDAR project in the past five years. Not only was it the first to implement the SOP version globally, but after the SOP was launched in Q2 2021, it leads the industry and achieved the first mass production delivery of the second-generation smart solid-state LiDAR.
M1 has smart software and hardware features under its small size appearance. In terms of smart hardware, M1 is based on the revolutionary two-dimensional MEMS smart chip scanning architecture, and has a unique "GAZE" function, which can adjust the scanning method according to the driving scene, improve the LiDAR perception ability, help enhance the automatic driving performance. In terms of smart software, M1 can be equipped with mature and embeddable point cloud AI perception algorithms.
At the same time, M1 guarantees the safety and reliability of point cloud data quality in various driving scenarios through a series of patented technologies, eliminates thorny problems in the industry from the product side, and built-in complete supporting functions such as OTA upgrade, stain detection, smart cleaning, smart heating, performance detection, power management, network management, etc. It has achieved SIL-2 and ASIL-B functional safety levels to help the vehicle perception system achieve ASIL-D functional safety design.
RoboSense will provide clients with continuously upgraded smart LiDAR system product solutions, jointly advance the evolution of smart driving experience, and accelerate the transformation and innovation of smart vehicle ecology. Promoting automated driving and advanced assisted driving passenger vehicles, commercial vehicles, logistics vehicles, robots, public smart transportation, and vehicle-road collaboration to achieve large-scale commercial use steadily and quickly.
About RoboSense (www.robosense.ai ):
RoboSense (Suteng Innovation Technology Co., Ltd.) is a world leading provider of Smart LiDAR Sensor Systems. It incorporates LiDAR sensors, AI algorithms and IC chipsets that transform conventional 3D LiDAR sensors to full data analysis and comprehension systems. The company's mission is to produce outstanding hardware and artificial intelligence capabilities to provide smart solutions that enable robots (including vehicles) to have perception capability superior to humans.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210820005135/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SLB Launches ExaCT Electrical Downhole CT Control System24.8.2026 13:02:00 CEST | Press release
New platform brings real-time electrical control to coiled tubing intervention, enabling greater precision, visibility and efficiency across intervention operations SLB (NYSE: SLB) today launched the ExaCT™ electrical downhole coiled tubing (CT) control system, an advanced intervention platform that introduces real-time electrical control to coiled tubing operations. By replacing pressure-dependent hydraulic actuation with electrical communication, power delivery and telemetry, the ExaCT system gives operators greater visibility, precision and control, helping improve intervention execution and reservoir access. The ExaCT system combines electrical power, telemetry and downhole measurements to enable communication with, actuation of and verification of downhole tools throughout an intervention. Continuous communication across the toolstring enables on-demand tool actuation across a wide range of intervention applications, including extended-reach and multilateral wells. The increased p
Wolters Kluwer Transforms Trusted Legal Content Into Structured, AI-Ready Intelligence That Powers the Next Wave of Legal AI24.8.2026 13:01:00 CEST | Press release
By transforming authoritative legal content into structured legal intelligence, Wolters Kluwer gives AI the context and relationships needed to deliver deeper research and higher-quality results Wolters KluwerLegal & Regulatory today announced the next evolution of Libra by Wolters Kluwer, its all-in-one Legal AI Workspace. By transforming authoritative legal sources, expert commentaries, and practical guidance into structured legal intelligence, Wolters Kluwer is making the relationships across the full breadth of its expert legal sources more explicit. This will enable deeper contextual research, more comprehensible answers, and workflow-ready results across legal work. Following the integration of Wolters Kluwer content into the Libra AI workspace in the first half of 2026, laws, rulings, expert commentaries, and practical guidance will now be linked to one another and to the matter at hand, creating a connected knowledge graph of expert-curated and authoredlegal knowledge that AI c
Daiichi Sankyo Appoints Markus Kosch to Lead Europe Business as Part of New Commercialization Organization24.8.2026 10:00:00 CEST | Press release
Daiichi Sankyo (TSE: 4568) today announced the appointment of Markus Kosch, MD, as Head of Europe Business, effective April 1, 2027. In this role, he will lead the company's European business within the new globally integrated Commercialization Unit and serve as General Manager of Daiichi Sankyo Europe GmbH, with legal responsibility for the company in Europe. The appointment reflects the next phase of growth of Daiichi Sankyo under its Five-Year Business Plan and the establishment of a new Commercialization Unit. Within this new structure, Markus Kosch will bring together the Oncology and Specialty businesses in Europe under one integrated leadership model to help bring innovative medicines to more patients across the region. For the past five years, Markus Kosch has led the Daiichi Sankyo Oncology Business Division in Europe and Canada, overseeing a period of significant growth and preparing the organization for an increasingly expanding oncology portfolio. Prior to joining Daiichi S
European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union24.8.2026 09:01:00 CEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older, making it the first and only treatment approved for Rett syndrome in the European Union (EU). “The approval of DAYBU marks a significant milestone for the Rett syndrome community in the EU and advances our mission to bring this innovative treatment to patients and families who have long faced a profound unmet medical need,” said Catherine Owen Adams, Acadia’s Chief Executive Officer. “For people living with Rett syndrome, a devastating rare neurodevelopmental disorder, there have been no approved treatment options in the EU. We are proud to make DAYBU available and look forward to supporting patients, caregivers, and healthcare providers gain access to treatment." The DAYBU marketing authorization in the EU is prim
ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 124.8.2026 08:36:00 CEST | Press release
Discovered by Takeda in Japan, ORZEYFUL has the Potential to Redefine Care Beyond Individual Symptom Management for Adults Living with Narcolepsy Type 1 (NT1) Landmark Phase 3 Studies Demonstrated Significant and Meaningful Improvements Across the Full Range of NT1 Symptoms Evaluated in Clinical Trials Compared to Placebo Milestone Marks Third Major Regulatory Approval Secured for ORZEYFUL Around the World Takeda (TOKYO:4502/NYSE:TAK) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved the use of ORZEYFUL (oveporexton) for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults. ORZEYFUL is a first-in-class oral orexin receptor 2 (OX2R) agonist and the only medicine indicated in Japan to treat the disease holistically rather than individual symptoms. The discovery of this new class of medicine originated in Takeda's laboratories in Japan. Takeda is proceeding with launch preparations and expects to make ORZEYFUL available as quickly
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
